https://finance.yahoo.com/news/kazia-provides-overview-paxalisib-related-123000266.html
"SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting. "The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies," stated Dr. John Friend, CEO Kazia. "We are highly encouraged with the preliminary overall survival data from the PNOC022 clinical study that we believe will provide an alternative to the current therapies considered as standard of care.""
- Forums
- International Markets
- Kazia
Kazia, page-13
Featured News
Featured News
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O’Donovan, Executive Director
Gerard O’Donovan
Executive Director
SPONSORED BY The Market Online